ASSIGNMENT AGREEMENTAssignment Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • New York
This Assignment Agreement is entered into as of November 21, 2019 (the “Assignment Effective Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California, 91320 (“Amgen”), and JASPER THERAPEUTICS, INC., a Delaware corporation having an address at 725 Mariposa Avenue, Mountain View, California, CA 94041 (“Jasper”).
CLINICAL TRIAL AGREEMENT For Clinical Trials Conducted at the National Institutes of Health Clinical Center BETWEEN THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AND JASPER THERAPEUTICS, INC. NIH Protocol # […***…] Jasper...Amplitude Healthcare Acquisition Corp • August 9th, 2021 • Biological products, (no disgnostic substances) • District of Columbia
This Agreement sets forth the terms and conditions under which this protocol will be conducted and the clinical trial will be managed.
AMENDMENT #2 TO THE INVESTIGATOR SPONSORED RESEARCH AGREEMENT AMGEN PROTOCOL NO. 20119244 BY AND BETWEEN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY FOR STANFORD UNIVERSITY, ON BEHALF OF […***…], AND AMGEN INC.Amplitude Healthcare Acquisition Corp • August 9th, 2021 • Biological products, (no disgnostic substances) • California
This Amendment #2 (this “Amendment”) to the Agreement (as defined below) is entered into as of November 15, 2017 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 3000 El Camino Real, Bldg 5, Suite 300, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Agreement.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...Material Transfer Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • New York
This Material Transfer Agreement (this “Agreement”) is made and entered into as of January 9, 2021 (the “Effective Date”) between Jasper Therapeutics, Inc., a Delaware corporation with a principal place of business at 2200 Bridge Pkwy Suit #102, Redwood City, CA 94065 (“Jasper”), and Graphite Bio, Inc., a Delaware corporation with a principal place of business at 279 E Grand Ave, Suite 430, South San Francisco, CA 94080 (“Graphite”). Jasper and Graphite are referred to each as a “Party” or collectively as the “Parties”, respectively.
EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and JASPER THERAPEUTICS, INC. Dated as of November 21, 2019 EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • New York
This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of November 21, 2019 (the “Effective Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California (“AMGEN”), and JASPER THERAPEUTICS, INC., a Delaware corporation having an address at 725 Mariposa Avenue, Mountain View, California CA 94041 (“JASPER”). JASPER and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MATERIAL TRANSFER AND OPTION AGREEMENTTransfer and Option Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • New York
This Material Transfer and Option Agreement (this “Agreement”) is made and entered into as of June 17, 2021 (the “Effective Date”) between Jasper Therapeutics, Inc., a Delaware corporation with a principal place of business at 2200 Bridge Pkwy Suit #102, Redwood City, CA 94065 (“Jasper”), and Aruvant Sciences GmbH, a company incorporated under the laws of Switzerland, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Aruvant”). Jasper and Aruvant are referred to each as a “Party” or collectively as the “Parties”, respectively.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Jasper Therapeutics, Inc. (“Jasper”), a corporation having a principal place of business at 2200 Bridge Parkway, #103, Redwood City, California 94065, is effective on the 25th day of March, 2021 (“Effective Date”).
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...Sponsored Research Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Agreement is between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having corporate powers under the laws of the State of California having an office at 415 Broadway Street, 2nd Floor, MC 8854, Redwood City, CA 94063, and JASPER THERAPEUTICS, INC., a Delaware corporation (“Company”), having its principal place of business at 2200 Bridge Parkway, Suite 102, Redwood City, CA 94065.
AMENDMENT #1 TO THE INVESTIGATOR SPONSORED RESEARCH AGREEMENT AMGEN PROTOCOL NO. 20119244 BY AND BETWEEN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY FOR STANFORD UNIVERSITY, ON BEHALF OF […***…], AND AMGEN INC.Amplitude Healthcare Acquisition Corp • August 9th, 2021 • Biological products, (no disgnostic substances) • California
This Amendment #1 (this “Amendment”) to the Agreement (as defined below) is entered into as of February 27, 2017 (the “Amendment Effective Date”) by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (“Amgen”) and The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 3000 El Camino Real, Bldg 5, Suite 300, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Agreement.
CLINICAL TRIAL AGREEMENT For Clinical Trials Conducted at the National Institutes of Health Clinical Center BETWEEN THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AND Jasper Therapeutics, Inc. Protocol # 16-I-0032Clinical Trial Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • District of Columbia
This Agreement sets forth the terms and conditions under which this Protocol will be conducted and the Clinical Trial will be managed.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...Quality Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances)
This Quality Agreement is intended by the Parties to set forth a plan for the quality assurance groups of AMGEN and STANFORD to work in relation to the manufacture, transfer, bulk labeling, packaging, testing, release, shipping and storage of the Product (as defined below). By signing below, the respective quality assurance representatives acknowledge and agree to the provisions of this Quality Agreement.
INVESTIGATOR SPONSORED RESEARCH AGREEMENT Amgen Protocol No. 20119244Investigator Sponsored Research Agreement • August 9th, 2021 • Amplitude Healthcare Acquisition Corp • Biological products, (no disgnostic substances) • California
This Investigator Sponsored Research Agreement (“Agreement”), effective as of June 18, 2013 (the “Effective Date”), is entered into by and between The Board of Trustees of the Leland Stanford Junior University for Stanford University, having a location at 1705 El Camino Real, Palo Alto, CA 94306 (“Institution”), on behalf of […***…] (“Principal Investigator”) and Amgen Inc., a Delaware corporation with its principal office and place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (hereinafter “Amgen”).
